You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《公司業績》中國生物製藥(01177.HK)首三季純利18.5億人幣跌18% 季息2港仙
阿思達克 11-30 16:33
中國生物製藥(01177.HK)公布截至今年9月底止首三季業績,營業額181.26億元人民幣(下同),按年跌6.2%。純利18.5億元,按年跌18%;每股盈利9.81分。派季度息2港仙。期內基本盈利為22.94億元,按年下跌11.7%。

期內新產品銷售收入佔集團總收入約36.7%,達到約66.59億元,較去年同期上升約66.9%;創新藥銷售額佔集團總收入約25%,去年同期佔比為約20%。

單計第三季,集團獲得臨床批件6件、生產批件11件及一致性評價獲批15個、申報臨床6件、一致性評價申報6個及申報生產2個。已累計有臨床批件、正在進行臨床試驗和申報生產的在研產品共398件,其中肝病用藥37件、抗腫瘤用藥190件、呼吸系統用藥22件、內分泌用藥20件、心腦血管用藥16件及其它類用藥113件。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account